Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
4.41B | 4.24B | 3.70B | 3.39B | 2.99B | 2.67B | Gross Profit |
4.07B | 3.93B | 3.44B | 3.19B | 2.84B | 2.54B | EBIT |
175.53M | 61.37M | 620.52M | 579.44M | 585.78M | -240.29M | EBITDA |
406.83M | 408.16M | 919.43M | 599.64M | 630.20M | -178.24M | Net Income Common Stockholders |
21.27M | 32.62M | 597.60M | 340.66M | 948.58M | -295.70M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
2.41B | 2.16B | 3.66B | 3.24B | 2.35B | 1.80B | Total Assets |
5.75B | 5.44B | 6.78B | 5.84B | 4.93B | 3.56B | Total Debt |
43.12M | 43.54M | 38.29M | 44.64M | 34.27M | 34.86M | Net Debt |
-1.90B | -1.64B | -3.18B | -2.91B | -2.02B | -1.48B | Total Liabilities |
2.08B | 2.00B | 1.59B | 1.47B | 1.16B | 949.65M | Stockholders Equity |
3.67B | 3.45B | 5.19B | 4.37B | 3.77B | 2.61B |
Cash Flow | Free Cash Flow | ||||
288.81M | 249.07M | 449.00M | 892.11M | 568.48M | -311.98M | Operating Cash Flow |
382.59M | 335.34M | 496.49M | 969.94M | 749.49M | -124.60M | Investing Cash Flow |
231.73M | 157.52M | -207.68M | -78.54M | -207.70M | -269.00M | Financing Cash Flow |
-2.02B | -2.02B | -20.03M | -794.00K | 6.18M | 71.71M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
81 Outperform | $12.73B | 11.68 | 22.69% | ― | 25.11% | 46.46% | |
80 Outperform | $11.56B | 19.23 | 30.22% | ― | 24.49% | 244.87% | |
79 Outperform | $13.88B | 12.28 | 19.94% | ― | 19.85% | 21.16% | |
71 Outperform | $11.04B | 21.35 | 9.64% | ― | 17.99% | 152.10% | |
71 Outperform | $12.44B | 198.78 | 0.47% | ― | 17.13% | -88.78% | |
53 Neutral | $5.14B | 3.03 | -44.09% | 2.83% | 16.75% | -0.06% | |
52 Neutral | $9.78B | ― | 357.68% | ― | 10.69% | 34.71% |
On May 11, 2025, Incyte Corporation and Novartis Pharma AG reached a settlement agreement concerning a litigation over royalty payments related to JAKAFI sales in the United States. Incyte agreed to pay Novartis $280 million for disputed royalties and to reduce future royalty rates by 50% starting January 1, 2025, impacting the company’s financial statements for the quarter ending June 30, 2025.
The most recent analyst rating on (INCY) stock is a Hold with a $59.00 price target. To see the full list of analyst forecasts on Incyte stock, see the INCY Stock Forecast page.